Statin therapy in patients hospitalized with acute myocardial infarction in central-western urban China from 2001 to 2011:the China PEACE-retrospective acute myocardial infarction study
Author:
Affiliation:

National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, China Oxford Centre for International Health Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China)

Clc Number:

R54

  • Article
  • | |
  • Metrics
  • |
  • Reference [26]
  • | | | |
  • Comments
    Abstract:

    Aim To illustrate patterns of statin therapy in patients with Acute Myocardial Infarction (AMI) in central-western urban China from 2001 to 2011, and identify factors affecting the use of statins. Methods A two-stage random sampling design was used to create a representative sample of patients who were admitted to hospital for AMI in central-western urban China in 1,6 and 2011. In the first phase, simple random-sampling procedure was used to identify participating hospitals. In the second phase, patients were selected from each sampled hospital in above 3 years through a systematic sampling approach. Medical records were centrally abstracted to get patients’ information. The findings were weighted for each year to represent the overall situation. Binary logistic regression analysis was used to identify factors related to the use of in-hospital statins. Results 31 randomly sampled urban hospitals in central-western China participated in the study, and 3 354 AMI admissions were included in analysis. There has been a significant increase in the use of statin therapy, the proportion of which was 19.7% in 1,9% in 2006, and 91.1% in 2011. Overall, statin use significantly increased among all low density lipoprotein-cholesterol (LDLC) groups during 10 years. Lovastatin was the most common stain in 2001 and it turned to be atorvastatin in 2011. Logistic regression analysis showed that patients who smoke (OR=1.36; 95% CI 1.07~1.73, P=0.011) were more likely to be treated with statin therapy. Conclusion During the past decade, the use of statin therapy has dramatically increased in central-western China. However, a lot still needs to be done to optimize the use of statin therapy among AMI patients.

    Reference
    [1] 国家心血管病中心.中国心血管病报告 2016.北京: 中国大百科全书出版社, 2016:121-136.
    [2] Ballantyne CM.Clinical lipidology: a companion to braunwald’s heart disease.Huston: Saunders/Elsevier, 2009: 227-257.
    [3] Baigent C, Keech A, Kearney PM, et al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins.Lancet, 5,6(9493):1 267-278.
    [4] Sacks FM, Pfeffer MA, Moye LA, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators.N Engl J Med, 6,5(14): 1 001-009.
    [5] Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4s) .Lancet, 4,4(8934): 1 383-389.
    [6] Amsterdam EA, Wenger NK, Brindis RG, et al.2014 aha/acc guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the american college of cardiology/american heart association task force on practice guidelines.J Am Coll Cardiol, 4,4(24): e139-228.
    [7] O'Gara PT, Kushner FG, Ascheim DD, et al.2013 accf/aha guideline for the management of st-elevation myocardial infarction: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines.Circulation, 3,7(4): 529-555.
    [8] Steg PG, James SK, Atar D, et al.Esc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation.Eur Heart J, 2,3(20): 2 569-619.
    [9] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南.中华心血管病杂志, 2,0(5): 353-367.
    [10] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志, 5,3(5): 380-393.
    [11] Roffi M, Patrono C, Collet JP, et al.2015 esc guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the european society of cardiology (esc) .Eur Heart J, 6,7(3): 267-315.
    [12] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版) .中国循环杂志, 6,1(10): 937-953.
    [13] 中华人民共和国国家统计局.中国统计年鉴2016.北京:中国统计出版社, 2016:89-95.
    [14] Chen Z, Launch of the health-care reform plan in China.Lancet, 9,3(9672): 1 322-324.
    [15] Dharmarajan K, Li J, Li X, et al.The china patient-centered evaluative assessment of cardiac events (china peace) retrospective study of acute myocardial infarction: Study design.Circ Cardiovasc Qual Outcomes, 3,6(6): 732-740.
    [16] Cannon CP, Brindis RG, Chaitman BR, et al.2013 accf/aha key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the american college of cardiology foundation/american heart association task force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards) .J Am Coll Cardiol, 3,1(9): 992-1 025.
    [17] Cheng TM.Early results of china's historic health reforms: the view from minister chen zhu, interview by tsung-mei cheng.Health Affairs (Project Hope), 2,1(11): 2 536-544.
    [18] Zhang LH, Li J, Li X, et al.National assessment of statin therapy in patients hospitalized with acute myocardial infarction: insight from china peace-retrospective ami study, 1,6, 2011.PLoS One, 6,1(4): e0150806.
    [19] Hanssen M, Cottin Y, Khalife K, et al.French registry on acute ST-elevation and non ST-elevation myocardial infarction 2010, FAST-MI 2010.Heart, 2,8(9): 699-705.
    [20] Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20 536 high risk individuals: a randomised placebo-controlled trial.Lancet, 2,0(9326): 7-22.
    [21] Cholesterol Treatment Trialists’ (CTT) Collaborators..Efficacy and safety of more intensive lowering of ldl cholesterol: a meta-analysis of data from 0,0 participants in 26 randomised trials.Lancet, 0,6(9753): 1 670-681.
    [22] 陈锐, 王昊天, 张抒扬.他汀类药物安全性研究进展.中国循环杂志, 2,7(2): 158-160.
    [23] 葛美玲, 朱振东, 黄志刚, 等.他汀类药物安全性的再评估.中国动脉硬化杂志, 5,3(3): 310-314.
    [24] Jones PH, Davidson MH, Stein EA, et al.Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) .Am J Cardiol, 3,2(2): 152-160.
    [25] Grundy SM, Cleeman JI, Merz CN, et al.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.J Am Coll Cardiol, 4,4(3): 720-732.
    [26] Cholesterol Treatment Trialists’ (CTT) Collaborators.The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.Lancet, 2,0(9841): 581-590.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

HUO Xi-Qian, ZHANG Li-Hua, HU Shuang, WU Chao-Qun, ZHANG Dan-Wei, LI Jing, LI Xi, ZHENG Xin, JIANG Li-Xin. Statin therapy in patients hospitalized with acute myocardial infarction in central-western urban China from 2001 to 2011:the China PEACE-retrospective acute myocardial infarction study[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2017,25(10):1047-1053.

Copy
Share
Article Metrics
  • Abstract:1036
  • PDF: 791
  • HTML: 0
  • Cited by: 0
History
  • Received:January 05,2017
  • Revised:April 15,2017
  • Online: November 28,2017
Article QR Code